The ICD in heart failure-time for a rethink?

New England Journal of Medicine

Volumn 375, Issue 13, 2016, Pages 1283-1284

  McMurray, John J V ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; MINERALOCORTICOID ANTAGONIST;

CARDIAC RESYNCHRONIZATION THERAPY; CARDIOVASCULAR MORTALITY; CAUSE OF DEATH; CLINICAL EFFECTIVENESS; CLINICAL PRACTICE; DEVICE THERAPY; DISEASE EXACERBATION; EDITORIAL; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE REVASCULARIZATION; HIGH RISK PATIENT; HUMAN; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; ISCHEMIC CARDIOMYOPATHY; NONISCHEMIC CARDIOMYOPATHY; PREMATURE MORTALITY; PRIORITY JOURNAL; RISK REDUCTION; SUDDEN CARDIAC DEATH; SYSTOLIC DYSFUNCTION; TREATMENT OUTCOME;

DEATH, SUDDEN, CARDIAC; DEFIBRILLATORS, IMPLANTABLE; HEART FAILURE; HUMANS; TREATMENT OUTCOME;

EID: 84989818608     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMe1609826     Document Type: Editorial

References (10)

1. Priori SG, Blomström-Lundqvist C, Mazzanti A, et al. 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: the Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC)-endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC). Eur Heart J 2015; 36: 2793-867.
2. Kadish A, Dyer A, Daubert JP, et al. Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopa-thy. N Engl J Med 2004; 350: 2151-8.
3. Desai AS, Fang JC, Maisel WH, Baughman KL. Implantable defibrillators for the prevention of mortality in patients with nonischemic cardiomyopathy: a meta-analysis of randomized controlled trials. JAMA 2004; 292: 2874-9.
4. Køber L, Thune JJ, Nielsen JC, et al. Defibrillator implantation in patients with nonischemic systolic heart failure. N Engl J Med 2016;375:1221-30.
5. Rush CJ, Campbell RT, Jhund PS, et al. Falling cardiovascu-lar mortality in heart failure with reduced ejection fraction and implications for clinical trials. JACC Heart Fail 2015; 3: 603-14.
6. Steinberg BA, Al-Khatib SM, Edwards R, et al. Outcomes of implantable cardioverter-defibrillator use in patients with co-morbidities: results from a combined analysis of 4 randomized clinical trials. JACC Heart Fail 2014; 2: 623-9.
7. Hess PL, Al-Khatib SM, Han JY, et al. Survival benefit of the primary prevention implantable cardioverter-defibrillator among older patients: does age matter? An analysis of pooled data from 5 clinical trials. Circ Cardiovasc Qual Outcomes 2015; 8:179-86.
8. McMurray JJV, Packer M, Desai AS, et al. Angiotensin-nepri-lysin inhibition versus enalapril in heart failure. N Engl J Med 2014;371:993-1004.
9. Velazquez EJ, Lee KL, Jones RH, et al. Coronary-artery by-pass surgery in patients with ischemic cardiomyopathy. N Engl J Med 2016;374:1511-20.
10. Pimentel M, Rohde LE, Zimerman A, Zimerman LI. Sudden cardiac death markers in non-ischemic cardiomyopathy. J Elec-trocardiol 2016;49:446-51.